We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+23.45%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$863M
AUM Growth
-$23.7M
Cap. Flow
-$77.7M
Cap. Flow %
-9.01%
Top 10 Hldgs %
80.4%
Holding
40
New
2
Increased
10
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
ELEV
Elevation Oncology
ELEV
+$1.71M
2
GBIO
Generation Bio
GBIO
+$489K
3
STAA icon
STAAR Surgical
STAA
+$88.9K
4
ANAB icon
AnaptysBio
ANAB
+$87K
5
BLUE
bluebird bio
BLUE
+$73.3K

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$88.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$27.3M
3
FOLD
Amicus Therapeutics
FOLD
+$3.23M
4
ALGN icon
Align Technology
ALGN
+$3.16M
5
EHTH icon
eHealth
EHTH
+$1.84M

Sector Composition

Rank Sector Weight
1 Healthcare 93.61%
2 Financials 1.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
26
DELISTED
Verve Therapeutics
VERV
$2.81M 0.33%
575,817
– –
NUVB icon
27
Nuvation Bio
NUVB
$2.25B
$2.26M 0.26%
772,652
– –
MIRM icon
28
Mirum Pharmaceuticals
MIRM
$6.04B
$2.21M 0.26%
64,700
– –
RLMD icon
29
Relmada Therapeutics
RLMD
$503M
$2.2M 0.25%
732,400
– –
TSHA icon
30
Taysha Gene Therapies
TSHA
$2.05B
$1.82M 0.21%
811,268
– –
STOK icon
31
Stoke Therapeutics
STOK
$2.13B
$1.7M 0.2%
125,861
– –
HUM icon
32
Humana
HUM
$46.7B
$1.49M 0.17%
3,985
– –
TVTX icon
33
Travere Therapeutics
TVTX
$5.86B
$910K 0.11%
110,719
– –
YARW
34
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
$878K 0.1%
8,909
– –
ALDX icon
35
Aldeyra Therapeutics
ALDX
$91.7M
$746K 0.09%
225,465
– –
ACRS icon
36
Aclaris Therapeutics
ACRS
$860M
$627K 0.07%
569,832
– –
GBIO
37
DELISTED
Generation Bio
GBIO
$424K 0.05%
+15,048
New +$489K
URGN icon
38
UroGen Pharma
URGN
$2.39B
$411K 0.05%
24,500
– –
ALNY icon
39
Alnylam Pharmaceuticals
ALNY
$30B
– –
-182,766
Closed -$27.3M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
FAM
Fulcrum Asset Management London, United Kingdom $662M AUM 48.09% 1-Year Est. Return

Palo Alto Investors's Q2 2024 Portfolio in Review

As of Q2 2024, Palo Alto Investors held 40 positions worth $863M, down 2.7% from $887M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Palo Alto Investors withdrew a net $77.7M in Q2 2024, closing 1 position and reducing 8 holdings. Its most notable exit was Alnylam Pharmaceuticals, an estimated $27.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 98% a quarter earlier, followed by Financials.

Against the trend, Palo Alto Investors opened a new position in Generation Bio worth $424K.

  • Palo Alto Investors's largest Q2 2024 buy was Generation Bio: 15,048 shares worth $424K.
  • Palo Alto Investors added most to Elevation Oncology in Q2 2024, an estimated $1.71M increase.
  • Palo Alto Investors's biggest Q2 2024 reduction was Insmed, cutting an estimated $88.6M.
  • Palo Alto Investors fully exited Alnylam Pharmaceuticals in Q2 2024, selling an estimated $27.3M.
  • Palo Alto Investors's ten largest holdings make up 80% of its $863M portfolio in Q2 2024.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q2 2024.
  • Palo Alto Investors's portfolio value fell 2.7% quarter-over-quarter to $863M.

Based on Palo Alto Investors's 13F filing for Q2 2024, filed 14 Aug 2024.